Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AZ sells Seroquel and Seroquel XR rights in North America to Cheplapharm

AZ sells Seroquel and Seroquel XR rights in North America to Cheplapharm

4th December 2019

The commercial rights to Seroquel and Seroquel XR, for the treatment of bipolar disorder and schizophrenia, in Canada and the US are currently owned by AstraZeneca. However, following the treatment’s loss of patent protection, the company has made the decision to sell the rights to Cheplapharm Arzneimittel GmbH (Cheplapharm), with a settled agreement of thirty-five million dollars upfront and potential payments in the future.

AZ’s Executive Vice President, BioPharmaceuticals Business Unit, Ruud Dobber, stated: “This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas. Cheplapharm recently agreed to acquire the commercial rights to Seroquel and Seroquel XR in most European markets and Russia from AstraZeneca and this new agreement will help ensure continued patient access to this important established medicine in North America as well.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.